Macquarie Group Ltd. decreased its position in Novartis (NYSE:NVS) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,150,212 shares of the company’s stock after selling 14,480 shares during the quarter. Macquarie Group Ltd.’s holdings in Novartis were worth $96,572,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fisher Asset Management LLC boosted its position in Novartis by 2.8% during the fourth quarter. Fisher Asset Management LLC now owns 6,816,625 shares of the company’s stock worth $572,324,000 after purchasing an additional 183,641 shares during the period. BlackRock Inc. boosted its position in shares of Novartis by 8.2% in the fourth quarter. BlackRock Inc. now owns 4,015,562 shares of the company’s stock valued at $337,146,000 after acquiring an additional 305,221 shares during the period. Aristotle Capital Management LLC boosted its position in shares of Novartis by 7.2% in the fourth quarter. Aristotle Capital Management LLC now owns 3,195,134 shares of the company’s stock valued at $268,263,000 after acquiring an additional 215,584 shares during the period. Mawer Investment Management Ltd. boosted its position in shares of Novartis by 3.5% in the fourth quarter. Mawer Investment Management Ltd. now owns 2,758,166 shares of the company’s stock valued at $231,576,000 after acquiring an additional 92,908 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Novartis by 9.4% in the third quarter. Parametric Portfolio Associates LLC now owns 1,719,039 shares of the company’s stock valued at $147,579,000 after acquiring an additional 148,197 shares during the period. 10.76% of the stock is owned by institutional investors and hedge funds.
NVS has been the subject of a number of recent research reports. JPMorgan Chase restated a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. UBS restated a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Nord/LB reiterated a “neutral” rating on shares of Novartis in a research note on Wednesday, December 27th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. Novartis presently has an average rating of “Hold” and a consensus target price of $87.51.
NVS traded down $0.86 during midday trading on Friday, reaching $80.20. 1,536,942 shares of the company were exchanged, compared to its average volume of 1,509,477. The stock has a market cap of $187,852.98, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 1.82 and a beta of 0.74. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. Novartis has a one year low of $72.67 and a one year high of $94.19.
Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The company had revenue of $12.92 billion for the quarter, compared to analyst estimates of $12.65 billion. During the same quarter last year, the firm posted $1.14 earnings per share. Novartis’s revenue was up 4.8% compared to the same quarter last year. equities analysts forecast that Novartis will post 5.33 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/macquarie-group-ltd-sells-14480-shares-of-novartis-ag-nvs.html.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.